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Ruthenium-based compounds show strong potential as anti-cancer drugs and are being investigated 
as alternatives to other well-established metal-based chemotherapeutics. The organometallic 
compound [Ru(η6-p-cymene)Cl2(pta)], where pta = 1,3,5-triaza-7-phosphaadamantane (RAPTA-C) 
exhibits broad acting anti-tumor efficacy with intrinsic angiostatic activity. In the search for an optimal 
anti-angiogenesis drug combination, we identified synergistic potential between RAPTA-C and the 
epidermal growth factor receptor (EGFR) inhibitor, erlotinib. This drug combination results in strong 
synergistic inhibition of cell viability in human endothelial (ECRF24 and HUVEC) and human ovarian 
carcinoma (A2780 and A2780cisR) cells. Additionally, erlotinib significantly enhances the cellular 
uptake of RAPTA-C relative to treatment with RAPTA-C alone in human ovarian carcinoma cells, but 
not endothelial cells. Drug combinations induce the formation of chromosome bridges that persist after 
mitotic exit and delay abscission in A2780 and A2780cisR, therefore suggesting initiation of cellular 
senescence. The therapeutic potential of these compounds and their combination is further validated  
in vivo on A2780 tumors grown on the chicken chorioallantoic membrane (CAM) model, and in a 
preclinical model in nude mice. Immunohistochemical analysis confirms effective anti-angiogenic 
and anti-proliferative activity in vivo, based on a significant reduction of microvascular density and a 
decrease in proliferating cells.
Metal-based chemotherapeutics including cisplatin, carboplatin and oxaliplatin have been used routinely in the 
clinic for decades and continue to represent the mainstay of treatment for many cancer types1. Despite the clinical 
success of platinum-based chemotherapeutics, their ability to prolong overall patient survival is often restricted 
by dose-limiting side effects, as well as intrinsic and acquired resistance2. Consequently, significant research 
efforts have focused on developing compounds based on other metals3.
In recent years, there has been particular interest in the development of ruthenium-based drugs and sev-
eral have been shown to exhibit clear anti-cancer activity in vitro and anti-tumor activity in various ani-
mal models4–6. Moreover, Ru-based compounds generally exhibit superior toxicity profiles compared to 
platinum-based compounds2,6. The Ru(III) compounds, KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)
ruthenate(III)]]7–9, KP1339 (the water soluble sodium salt of KP1019)10,11 and NAMI-A [imidazolium 
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trans-[tetrachloro(dimethylsulfoxide)(1H-imidazole)ruthenate(III)]]12 have completed phase I and phase I/II 
trials, for NAMI-A in combination with gemcitabine13, and are expected to undergo further clinical evaluation. 
In addition to Ru(III) compounds, a number of promising Ru(II)-based compounds have been evaluated various 
in vivo models14. For example, [Ru(η6-p-arene)Cl(en)]+(arene = p-cymene or biphenyl, en = ethylenediamine) 
was shown to reduce the growth of primary tumors4,15.
The compound [Ru(η6-p-cymene)Cl2(pta)], where pta = 1,3,5-triaza-7-phosphaadamantane (RAPTA-C) 
was originally only shown to have anti-metastatic properties16 and, subsequently, was shown to exhibit primary 
anti-cancer effects by inducing apoptosis in Ehrlich ascites carcinoma cells17. While the mechanism of action of 
RAPTA-C still remains to be fully elucidated, it has been suggested that the formation of adducts in chromatin 
histone proteins are involved18. This mechanism is different to that observed for the ruthenium(III) compounds 
mentioned above19–21. We have also demonstrated the effect of RAPTA-C on the suppression of primary tumor 
growth in preclinical studies22. In addition to targeting cancer cells directly, strong anti-angiogenic activity has 
been demonstrated both in vitro and in vivo23.
Extensive studies have been undertaken to modify the structure of Ru(II) compounds to improve their drug 
efficacy24,25, while much less effort has been directed towards elucidating drug combinations13,26, despite the 
latter approach being well-established in enhancing therapeutic efficacy27,28. For instance, targeted therapies 
have been shown to enhance the effect of classical chemotherapy by reducing the likelihood of acquired drug 
resistance resulting in prolonged patient survival29,30. However, only few drug combination studies investigating 
metal-based drugs that do not contain platinum have been performed. For instance, combinations of NAMI-A 
and 5-fluorouracil, cisplatin or doxorubicin showed superior activity compared to either chemotherapeutic alone 
in various pre-clinical cancer models31–33. However, in a recent phase I/II trial in NSCLC patients, NAMI-A and 
gemcitabine did not show enhanced activity13. Furthermore, another Ru-based compound, KP1339, was recently 
found to synergistically improve the effect of the multi-kinase inhibitor sorafenib in hepatoma cancer in vitro and 
in vivo26.
In a recent study employing an algorithm-based screening method incorporating a broad selection of targeted 
drugs, we optimized an angiostatic drug combination for the treatment of cancer34. This study hinted towards 
dose-dependent synergistic interactions between RAPTA-C and the epidermal growth factor receptor (EGFR) 
inhibitor, erlotinib/Tarceva® in various in vitro and in vivo models34. Erlotinib is a small molecule tyrosine 
kinase inhibitor (TKI) targeting EGFR and with lower affinity also targeting serine/threonine kinases (i.e. cyc-
lin G-associated kinase, serine/threonine-protein kinase 10 and STE20-like serine/threonine-protein kinase)35. 
It is currently approved for the treatment of non-small cell lung cancer and for the treatment of pancreatic cancer 
in combination with gemcitabine36. Erlotinib competes with ATP binding to the tyrosine kinase domain of EGFR 
and has been shown to act through the inhibition of cell proliferation and the induction of cell cycle arrest in 
cancer cells37,38. Importantly, through the blockage of EGFR and its downstream ras/raf/MEK/MAPK signalling 
pathway, erlotinib also inhibits the release of pro-angiogenic factors, including vascular endothelial growth factor 
(VEGF), interleukin 8 (IL8) and fibroblast growth factor (FGF)39,40. As erlotinib and RAPTA-C both act through 
anti-cancer and anti-angiogenic mechanisms, their combination might be beneficial in the treatment of aggres-
sive tumor types.
For the current study, we undertook a detailed evaluation of the therapeutic potential of the erlotinib/
RAPTA-C combination by identifying effective drug dose ratios and studying the mechanism of action of this 
drug combination. Studies were performed in vitro using endothelial and human A2780 ovarian carcinoma cells, 
as well as in A2780 cells with acquired resistance to cisplatin (A2780cisR). The in vitro experiments were sub-
sequently validated in vivo using the chicken chorioallantoic membrane (CAM) model grafted with A2780 or 
A2780cisR tumors, and in nude mice bearing A2780 tumors. The results presented here show the effective activity 
of these two compounds when administered simultaneously, leading to effective tumor growth inhibition.
Results
Cell viability and migration assays. The effect of erlotinib and RAPTA-C on cell viability was investigated 
in immortalized (ECRF24) and primary (HUVEC) human endothelial cells (ECs), as well as in human A2780 
ovarian carcinoma cells and a cisplatin-resistant variant of this cell line, A2780cisR (Fig. 1A). Dose response 
curves for both compounds applied as mono-therapies were previously reported for the ECRF24 cell line34 and 
were prepared for the other cell lines (data not shown). We selected a dose range that inhibits cell viability by 
ca. <40% based on these curves (for erlotinib <15 μM and for RAPTA-C <200 μM). Notably, combinations of 
erlotinib/RAPTA-C significantly inhibited cell viability (erlotinib 10 μM/RAPTA-C 10 μM, marked as combina-
tion I, and erlotinib 5 μM/RAPTA-C 100 μM, marked as combination II; Fig. 1A and Supplementary Figure 1 
for other investigated dose ratios). Measurement of absolute cell numbers in A2780 and A2780cisR cells showed 
that the cell count for erlotinib/RAPTA-C treated cells did not increase much (indicative of halted cell prolifer-
ation) whereas the cell count of non-treated cells tripled after 72 hours (Fig. 1B). This difference suggests that 
erlotinib/RAPTA-C combinations induce a state of cellular senescence, as the cell number also does not decrease 
(which would be suggestive of cell death). Interestingly, assessment of A2780 and A2780cisR cell counts closely 
resembled the activity on cell viability at 24, 48 and 72 hours of treatment (Supplementary Figure 2). To assess 
specificity and potential toxicities, the activity of erlotinib and RAPTA-C was tested in the non-malignant cells 
types human embryonic kidney cells and peripheral blood mononuclear cells (HEK-293 and PBMCs respectively; 
Supplementary Figure 3). PBMC and HEK cell viability was only minimally affected by either erlotinib, RAPTA-C 
or their combinations, suggesting increased specificity towards activated endothelial cells and cancer cell types, 
and a favourable toxicity profile of the drug combination.
To investigate possible synergies between erlotinib and RAPTA-C, the combination index (CI) was deter-
mined for each drug combination (Fig. 1A and Supplementary Table 1). A CI < 1 indicates a synergistic effect, 
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when CI = 1 the effect is additive and, a CI > 1 corresponds to antagonism. Synergistic efficacy (CI < 1) was 
observed for nearly all of the combinations tested in all cell types.
The effect of varying drug administration schedules on the overall efficacy of drug combinations in the 
ECRF24 and A2780 cell lines in vitro was additionally investigated. Thus, the efficacy of each combination was 
examined when adding one drug 2 h prior to the addition of the other drug, and vice versa. A comparison of both 
dosing schedules on cell viability inhibition revealed no significant differences that could be attributed to the 
administration schedule (data not shown).
We further evaluated the activity of erlotinib/RAPTA-C combinations on their ability to inhibit the mobility of 
ECRF24 (endothelial-), A2780 and A2780cisR (cancer-) cells using the scratch wound assay. Scratches were made 
in a confluent cell layer and relative wound closure was determined. Neither single drug nor any of the evaluated 
drug combination inhibited the mobility of the ECRF24 cells significantly, which is in concordance with results 
from our previous study34. It should be noted that in the scratch wound assay, cells are only treated for a period 
of 6 h, whereas cell viability is assessed after a 72 h period of exposure to the compounds, which may partially 
account for the limited activity observed in the scratch wound assay (Supplementary Figure 1).
To visualize the relationship between varying concentrations of erlotinib/RAPTA-C and the drug combination 
efficacy (in terms of cell viability inhibition), response surfaces were constructed for each cell type. The shape of 
the response surface differs between cell types (Fig. 2A). Response surfaces were used to identify the combina-
tions to be used in the in vivo models. The starred dose ratio combinations (erlotinib 10 μM/RAPTA-C 10 μM, 
marked as I, and erlotinib 5 μM/RAPTA-C 100 μM, marked as II in Fig. 2A), were selected for translation to 
in vivo testing as they represent the minimal drug dosages within the area of the response surface showing 
Figure 1. Activity of erlotinib and RAPTA-C on endothelial and ovarian cancer cell viability (A) and on total 
cell coverage per μm2 surface (B). (A) Inhibition of cell viability by erlotinib, RAPTA-C and their combinations 
in endothelial cells (immortalized ECRF24 and primary human umbilical vein endothelial cells; HUVEC) and 
ovarian cancer cells (A2780 and A2780cisR). The combination of erlotinib 5 μM/RAPTA-C 10 μM, erlotinib 
10 μM/RAPTA-C 10 μM (marked as I) and erlotinib 5 μM/RAPTA-C 100 μM (marked as II) are shown. Cell 
viability was assessed after 72 h of drug treatment by the CellTiter-Glo luminescence assay and represented as a 
percentage of the control. Combination index (CI) values per cell line for erlotinib/RAPTA-C combinations are 
shown. Significance is indicated vs. CTRL (0.14% DMSO-treated cells), with *P < 0.05 and **P < 0.01, based on a 
one-way ANOVA with post-hoc Tukey’s test (ECRF24: F(19, 219) = 13.69, P < 0.0001; HUVEC: F(19, 175) = 16.83, 
P < 0.0001; A2780: F(19, 85) = 10.86, P < 0.0001; A2780cisR: F(19, 205) = 58.2, P < 0.0001). (B) Total cell coverage 
of A2780 and A2780cisR cells attached to the bottom of a 96-well plate. Total cell coverage was assessed at 0, 24, 
48 and 72 hours of drug treatment and automatically measured and quantified. Values shown represent absolute 
values of the total surface in μm2 occupied by cells. Values represent the mean of at least one experiment performed 
in triplicate and error bars represent the SEM.
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maximal efficacy (red/orange region of the surface), for A2780cisR (combination I) and A2780 (combination II). 
Moreover, both combinations result in similar inhibition of the endothelial cell types HUVEC and ECRF24, thus 
supporting an anti-proliferative effect of both combinations in endothelial cell types.
Cellular ruthenium uptake. It was previously reported that intracellular accumulation of Ru may account 
for synergistic interactions between KP1339 and sorafenib26. To investigate a possible similar mechanism under-
lying the observed synergies, the cellular uptake of ruthenium was analysed using inductively coupled plasma 
mass spectrometry (ICP-MS) in each cell line following a 5 h exposure period to the selected, optimal drug 
Figure 2. Response surfaces of ovarian cancer- and endothelial cell viability inhibition with respect to 
varying doses of erlotinib/RAPTA-C in combination treatments and cellular uptake of Ru in ovarian cancer 
cells. (A) Images show a visual representation of the effect, in terms of cell viability inhibition, of systematically 
varying the drug concentrations comprising erlotinib and RAPTA-C combinations. A range is shown from low 
efficacy (blue) to high efficacy (red). The orange star represents combination I; erlotinib/RAPTA-C (10/10 μM)  
and the green star represents combination II; erlotinib/RAPTA-C (5/100 μM). These dose-ratios were selected 
for translation to in vivo experiments. The input data used to generate the response surfaces are shown in 
Fig. 1A and Supplementary Figure 1. (B) Cellular uptake of Ru in each cell line for the optimal combination 
identified in cell proliferation assays. Values represent the mean Ru102 signal parts per billion (ppb) normalized 
to the protein content (per μg of protein) of each sample from one experiment performed in triplicate with error 
bars representing the SEM. Significance is indicated for combination treatment vs. the RAPTA-C single drug 
treatment group (*P = 0.028 and 0.045 in A2780 and A2780cisR cells, respectively; *P < 0.05 and **P < 0.01).
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combination or the corresponding RAPTA-C dose alone (Fig. 2B). Ru accumulates in the cancer cells at both 10 
and 100 μM concentrations of RAPTA-C (1.08 mean Ru102 signal (ppb/μg of protein) at 100 μM in A2780 and 0.45 
(ppb/μg of protein) at 10 μM in A2780cisR). Furthermore, erlotinib enhances the uptake of Ru in both cancer cell 
lines significantly as compared to RAPTA-C administered alone (i.e. erlotinib induced increase in mean Ru102 
signal of 0.46 (ppb/μg of protein) in A2780 and 0.38 (ppb/μg of protein) in A2780cisR; Fig. 2B).
RAPTA-C at a 10 μM dose is not observed to accumulate in ECRF24 cells, whereas exposure to 100 μM of 
RAPTA-C results in significant Ru uptake (mean Ru102 signal 0.09 (ppb/μg of protein) and 1.23 (ppb/μg of pro-
tein) for RAPTA-C 10 μM and 100 μM, respectively). The addition of erlotinib to these RAPTA-C concentrations 
did not change the Ru uptake in ECRF24 cells for either drug combination (mean Ru102 signal 0.01 (ppb/μg of 
protein) and 1.18 (ppb/μg of protein) for combination I and II, respectively).
Mechanism of cell death induced by erlotinib/RAPTA-C combinations. To investigate the mech-
anism of cell death of erlotinib/RAPTA-C combinations in ECs and ovarian carcinoma cells, DNA profiles were 
assessed by flow cytometry analysis after staining with propidium iodide (PI). Sunitinib (10 μM) was included in 
the assays as a positive control for apoptosis41. While the single drug treatments did not induce significant apopto-
sis, combination I and II lead to the induction of apoptosis (e.g. 16.3% and 16.7% apoptosis induction in ECRF24 
cells for combination I and II, respectively, Fig. 3A). Interestingly, in both A2780 and cisplatin-resistant A2780 
(A2780cisR) cells, only a minor induction of apoptosis was observed (Fig. 3A and Supplementary Figure 4A for 
other investigated dose ratios).
To further explore the mechanism of the synergistic anti-proliferative activity of erlotinib/RAPTA-C com-
binations the cell cycle distribution was analysed. In all the cell types tested, no clear G2/M- or S-phase arrest 
was observed for erlotinib, RAPTA-C or their combinations compared to controls (shown for ECRF24 cells in 
Supplementary Figure 4B). Furthermore, the differences in S-phase, G0/G1 and G2/M phases for all the con-
ditions tested were only marginally (not significantly) distinct compared to the controls. These data indicate 
that apoptosis induction contributes to the mechanism by which the erlotinib/RAPTA-C combination induces 
cell death in ECRF24 and HUVEC cells, but not in A2780 and A2780cisR cells. In addition, in both A2780 and 
A2780cisR cells, the induction of autophagy was studied since the erlotinib/RAPTA-C treatment did not result 
in clear apoptosis induction and there is evidence suggesting that the induction of autophagy is an alternative 
route to cell death42. However, erlotinib/RAPTA-C treatment did not result in an increase in the formation of 
autophagic vacuoles in either cell lines (Supplementary Figure 5).
In the next step, we controlled whether treatment with combination II affected the expression of FAK (Fig. 3B), 
known to be enhanced in human ovarian cancer and linked with ovarian carcinoma dissemination43. The immu-
noblotting results revealed attenuated FAK expression by combination II in A2780 cells, which can be seen by the 
decreased intensity and thickness of corresponding western blot bar (Fig. 3B). However, neither phosphorylated 
FAK, AKT or ERK was affected by the combination treatment in A2780 cells (Supplementary Figure 6). Moreover, 
Rhodamine-Phalloidin staining against actin (Fig. 3C in red) revealed that treated cells appeared more rounded 
and showed a tendency to aggregate. Additionally, the polymerization of actin was clearly disrupted and stress 
fibers were decreased. The stained actin fibers in the treated cells were condensed in the cell periphery as com-
pared to the central part of the cell in the CTRL group. Moreover, pertusions visible in CTRL cells were attenuated 
in combinations and monotherapy-treated cells. These phenomena were previously reported in FAK-deficient 
cells44. Levels of phosphorylated proteins were not altered (Supplementary Figure 7).
To detect potential defects in actin organization and cellular morphology, we next stained cells after 24 hours 
of treatment with fluorescent phalloidin (actin marker) and DAPI (DNA marker; Fig. 3C,D, blue). After 
treatment with combination I (**P < 0.01 vs. CTRL, one-way ANOVA), and to lesser extend combination II 
(**P < 0.01 vs. CTRL, one-way ANOVA), we observed in A2780 and A2780cisR cells, but not in ECRF24 cells 
(Supplementary Figure 6), a significant increase in the number of DNA bridges (Fig. 3C, right column, top image, 
yellow arrows). Such DNA-bridges arise as a consequence of entering mitosis with partially unreplicated DNA, 
chromosome fusions or as a result of severe chromosome segregation errors45. These cells also frequently dis-
played micronuclei (Fig. 3C, right column, middle image), another marker for chromosome segregation errors or 
chromosome breakages, which is linked to genomic instability and chromosomal damage46. DNA bridges persist 
after mitotic exit, delay abscission and can lead to a cytokinesis failure and tetraploidization47. Consistent with 
such a hypothesis, cells with DNA bridges often contained remnants of the cytokinetic rings, implying cytokinesis 
failure (Fig. 3C, right column, bottom image). Thus, combinations I and II did not alter cell cycle progression, but 
the outcome of cell division in A2780 and A2780cisR cells.
Evaluation of the in vivo anti-vascular effects of erlotinib/RAPTA-C combinations. The inhibi-
tion of new vascular sprout formation was evaluated in the chicken chorioallantoic membrane (CAM) model48 
following vaso-occlusive Visudyne®-photodynamic therapy (PDT)49. Application of PDT to the CAM vascula-
ture leads to occlusion of blood vessels, which results in the induction of angiogenesis and revascularization of the 
treated tissue49. This model of induced angiogenesis is used between embryo development day (EDD) 11 and 12, 
when neo-vascularization is complete. The activity of erlotinib/RAPTA-C combinations was investigated in this 
model based on the intravenous (i.v.) administration of the drugs applied directly after PDT treatment (Fig. 4A). 
In the control group, 24 h post-PDT, vascular sprouts (indicated by green arrows) were observed growing from 
the rim of the PDT-treated area towards the center of the treatment zone (Fig. 4A). In the group treated with 
erlotinib/RAPTA-C, a reduced number of sprouts, in addition to occluded blood vessels (indicated by red arrows) 
were observed. Quantification of vascular sprouts showed a significant decrease in the number of sprouts for both 
combinations tested (Fig. 4B; **P < 0.01 vs. CTRL for combination I and **P < 0.05 vs. CTRL for combination II). 
In addition, combination II, but not combination I, significantly decreased the number of branching points (i.e. 
the number of branches from which a sprout develops), while neither of the single drug treatments affected 
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the number of branching points (Fig. 4B; *P < 0.05 vs. CTRL). Taken together, these results are indicative of an 
anti-angiogenic effect of the drug combinations.
Inhibition of tumor growth in the CAM model by erlotinib/RAPTA-C combinations. The effect 
of selected erlotinib/RAPTA-C combinations was investigated on the growth of both human A2780 tumors 
and their cisplatin resistant counterparts (A2780cisR) in the CAM model. In this model, fertilized chicken eggs 
were incubated in a hatching incubator and on embryo development day (EDD) 8, tumor cells were implanted 
onto the chorioallantoic membrane after which vascularized three-dimensional tumors appeared by EDD11. 
In the translation of drug doses from in vitro to in vivo, the drug dose-ratios were maintained while taking into 
account the suboptimal single drug efficacies previously tested (erlotinib 5 μM and 10 μM in vitro correspond to 
10 μg/kg/day and 20 μg/kg/day in vivo; RAPTA-C 10 and 100 μM in vitro correspond to 21.6 and 216 μg/kg/day in 
vivo)34. Tumors were treated by 20 μl i.v. injections on treatment days 1 and 2 (EDD 11/12) and drug doses were 
Figure 3. Apoptosis induction in human endothelial- and ovarian carcinoma cells, and the formation of 
DNA bridges and micronuclei in ovarian carcinoma cells. Apoptosis and cell cycle distributions were assessed 
using flow cytometry analysis based on propidium iodide (PI) staining of DNA. Sunitinib (10 μM) was used as 
a positive control. The combination consisting of erlotinib 10 μM/RAPTA-C 10 μM is marked as I and erlotinib 
5 μM/RAPTA-C 100 μM is marked as II. (A) Apoptosis induction in ECRF24, HUVEC, A2780 and A2780cisR 
cells. (B) Western Blot analysis of erlotinib/RAPTA-C treatment in A2780 cells. Cells were treated for 2 h after 
which cell lysates were prepared. Immunoblotting was performed using FAK, AKT and ERK antibodies. GAPDH 
was included as a loading control. *P < 0.05, **P < 0.01 indicate significance vs. the control. (C) Representative 
images of staining for DAPI (blue) and phalloidin (red) in A2780 cells. The yellow arrows indicate DNA bridges 
and the green arrows indicate micronuclei. (D) Quantification of DNA Bridges between nuclei and quantification 
of micronuclei in DAPI stained A2780 cells. Statistical analysis was performed with a one-way ANOVA (A2780 
bridges: F (6, 29) = 4.739, P = 0.0018; A2780 micronuceli: F (6, 29) = 3.293, P = 0.0135; A2780cisR bridges: F (6, 
28) = 8.650, P > 0.0001; A2780cisR micronuceli: F (6, 28) = 2.469, P = 0.0482). Values represent the mean of at 
least one experiment performed in triplicate and error bars represent the SEM. 
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adjusted based on the average chicken embryo weight on EDD 11/12. It was found that treatment of A2780 tum-
ors with single drugs alone inhibited tumor growth by <20%, whereas the evaluated drug combinations inhibited 
tumor growth by 34% (combination I; vs. CTRL; not significant; CI = 0.73) and 64% (combination II; vs. CTRL; 
**P < 0.0001; CI = 0.34) on the last day of the experiment (Fig. 5A). These data were confirmed by measurement 
of tumor weight following resection (vs. CTRL; *P < 0.05; Fig. 5C). Macroscopic images of tumors resected on 
treatment day 8 show a clear reduction in tumor size, as well as differences in tumor morphology. Control and 
single drug treated tumors appear heterogeneous in size and colour while the combination treated tumors are 
generally less vascularized (indicated by the pale colour) and appear to be more homogeneous (Fig. 5B). The 
microvessel density (MVD) in treated A2780 tumors was quantified by staining for the endothelial cell marker 
CD31 in tumor sections. Interestingly, treatment with erlotinib (10 μg/kg/day) or RAPTA-C (216 μg/kg/day) 
alone resulted in a decrease in MVD (by 27% and 22%, respectively, Fig. 5D). Treatment with combinations 
of both compounds decreased MVD by 37% (combination I; **P < 0.01; Fig. 5) and by 34% (combination II; 
*P < 0.05; Fig. 5D).
The synergistic inhibition of A2780 tumor growth by erlotinib/RAPTA-C combinations can, at least in part, 
be attributed to the inhibition of angiogenesis based on the reduction in MVD seen in treated tumors. It is note-
worthy that while combination I only slightly inhibited overall tumor growth as compared to single drug treat-
ments (not significant vs. CTRL), it did result in significant inhibition of MVD (37%, **P < 0.01). This result is 
Figure 4. Activity of erlotinib/RAPTA-C combinations on the CAM vasculature. (A) Fluorescence 
angiogram of PDT induced neo-vascularization on the CAM after treatment with erlotinib, RAPTA-C 
and erlotinib/RAPTA-C combinations. The yellow circle shows the PDT-treated area with ongoing 
revascularization. Green arrows show vascular sprout formation as result of PDT treatment. Red arrows indicate 
occluded blood vessels. (B) Quantification of the number of sprouts, the average length of vascular sprouts and 
the number of branching points per mm2 was performed using ImageJ. Drug administration was performed 
directly after PDT and fluorescence angiograms were recorded 24 h after treatment. Erlotinib/RAPTA-C 
(10/10 μM) and erlotinib/RAPTA-C (5/100 μM) are referred to as combination I and II, respectively. The white 
bars represent 200 μm and are valid for all images with the corresponding magnification. N = 5–6 eggs. Values 
represent the mean and error bars represent SEM. Statistical analysis was achieved using a one-way ANOVA 
test with post-hoc Dunnett’s multiple comparison between the combination and control groups only (number 
of sprouts: F(2,31) = 3.51, P = 0.0415; average segment length: F(2,14) = 7.607, P = 0.0058; branching points per 
mm2: F(3,9) = 5.63, P = 0.0188). *P < 0.05 and **P < 0.01 indicate significance vs. the CTRL (0.14% DMSO).
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supported by the response surfaces provided in Fig. 2 where both combinations show a similar range of efficacy 
in the endothelial cell lines. However, a clear difference in activity of each combination is observed in the A2780 
cell line since combination II has a much stronger inhibitory effect on tumor cell proliferation (58% cell viability 
inhibition) compared to combination I (31% cell viability inhibition).
To assess the effect of drug treatment on the amount of proliferating cells, tumor tissues were stained for 
the proliferation marker Ki67. Quantification of Ki67+ staining in whole tumor surfaces revealed a significant 
decrease of the percentage of Ki67+ tissue for combination I only (37% inhibition vs. CTRL; *P < 0.05; Fig. 5E). 
Representative images of treated tumors show a decrease of tissue with viable proliferating cells (Fig. 5G). Since 
cisplatin is the first-line treatment for patients with high-stage ovarian carcinoma, the in vivo activity of erlo-
tinib/RAPTA-C combinations was also determined on A2780 tumors with an induced resistance to cisplatin. 
This might demonstrate a therapeutic potential in the treatment of patients with ovarian carcinoma showing 
Figure 5. Inhibition of A2780 tumor growth in the CAM model by erlotinib, RAPTA-C and combination 
treatments. (A) Tumor growth curves of A2780 tumors grafted on the CAM showing tumor volume with 
respect to treatment day represented as the percentage of the final control tumor volume. S indicates synergy 
(CI < 1). N = 30 in the control group and N = 4–14 in the treatment groups (two-way ANOVA: F(6,555) = 8.994, 
P < 0.0001). (B) Representative images of resected tumors in each treatment group. Control tumors were treated 
with 0.14% DMSO in NaCl. (C) Tumor weight (mg) after resection on treatment day 8 (when the experiment was 
terminated (one-way ANOVA: F(2, 48) = 3.35, P = 0.04)). (D) Microvessel density (MVD) analysis measured 
as the number of vessels per mm2 of vascularized tumor area and represented as percentage of control (one-
way ANOVA: F(2, 25) = 15.23, P < 0.0001). (E) Quantification of the percentage of whole tumor sections that 
are positive for the proliferation marker Ki67 (one-way ANOVA: F(2, 27) = 4.25, P = 0.025) (F) Representative 
images of immunohistochemical (IHC) staining for the endothelial cell marker CD31 (brown) counter-stained 
with haematoxylin (purple/blue). (G) Representative images of IHC staining for the proliferation marker Ki67 
(brown/orange) counter-stained with haematoxylin (purple/blue). I indicates the combination erlotinib 20 μg/kg/
day + RAPTA-C 21.6 μg/kg/day and II indicates the combination erlotinib 10 μg/kg/day + RAPTA-C 216 μg/kg/
day in all graphs. Error bars represent SEM and *P < 0.05, **P < 0.01 indicate significance versus CTRL. Statistical 
analysis was performed using a two-way ANOVA with post-hoc Tukey’s multiple comparison test (A) or one-way 
ANOVA with post-hoc Dunnett’s multiple comparison test between the combination and control (C–E).
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resistance to standard therapy. We hypothesized, based on the in vitro data, that erlotinib/RAPTA-C combination 
treatment may efficiently inhibit tumor growth in the A2780cisR ovarian carcinoma tumors as the drug combi-
nation appears to operate via a different mechanism than that of cisplatin. Similar to the tumors developed from 
treatment naïve A2780 cells, single drug administration only slightly reduced A2780cisR tumor growth (Fig. 6A). 
Treatment with combination I resulted in 58% inhibition of tumor growth (**P < 0.01 vs. CTRL and single 
drug treatments; CI = 0.07) on the last treatment day. For combination II, tumor growth inhibition of 67% was 
observed (**P < 0.01 vs. CTRL; CI = 0.69). Notably, embryo weight was assessed on the last day of the experiment 
and was not significantly affected by any combination treatment in either tumor model (Supplementary Figure 8), 
suggesting a lack of toxicity of the combination treatments.
Interestingly, while combination II treated tumors showed similar efficacy in A2780 and A2780cisR (64% vs. 
67% tumor growth inhibition respectively), combination I is more effective in A2780cisR tumors as compared to 
Figure 6. Inhibition of A2780cisR tumor growth in the CAM model by erlotinib, RAPTA-C and their 
combination treatment. (A) Tumor growth curves of A2780cisR tumors grafted on the CAM showing tumor 
volume with respect to treatment day, represented as the percentage of the final control tumor volume. S 
indicates synergy. N = 20 in the control group and N = 7–15 in the treatment groups. Control tumors were 
treated with 0.14% DMSO in NaCl (two-way ANOVA: F(6,550) = 4.692, P = 0.0001). (B) Tumor weight (mg) 
after resection at treatment day 8 (when the experiment was terminated; not significant, one-way ANOVA: 
F(2,54) = 3.05, P = 0.055). (C) Microvessel density (MVD) analysis measured as the number of vessels per 
mm2 of vascularized tumor area and represented as percentage of control (one-way ANOVA: F(2,31) = 5.641, 
P = 0.0081). (D) Quantification of the percentage of whole tumor surfaces that are positive for the proliferation 
marker Ki67 (one-way ANOVA: F(2,34) = 4.67, P = 0.016). (E) Representative images of IHC staining for the 
endothelial cell marker CD31 (brown) counter-stained with haematoxylin (purple/blue). (F) Representative 
images of IHC staining for the proliferation marker Ki67 (brown/orange) counter-stained with haematoxylin 
(purple/blue). I indicates the combination erlotinib 20 μg/kg/day + RAPTA-C 21.6 μg/kg/day and II indicates 
the combination 10 μg/kg/day + RAPTA-C 216 μg/kg/day in all graphs. Error bars represent SEM and *P < 0.05, 
**P < 0.01 indicate significance versus CTRL. Statistical analysis was performed using a two-way ANOVA 
with post-hoc Tukey’s multiple comparison test (A), or one-way ANOVA with post-hoc Dunnett’s multiple 
comparison test between the combination and control (B–D).
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the non-resistant variant (34% vs. 58% tumor growth inhibition for A2780 and A2780cisR tumors, respectively). 
This difference in activity is supported by the response surfaces shown in Fig. 2. In particular, a clear lack of 
activity of combination I can be seen in the A2780 cell line while its activity in the A2780cisR cell line is relatively 
strong.
Quantification of CD31 stained A2780cisR tumor sections revealed a decrease in MVD for erlotinib and 
RAPTA-C mono-therapies (i.e. 19% for erlotinib at 20 μg/kg/day and 28% for RAPTA-C at 216 μg/kg/day, 
Fig. 6C). In both cases, tumor growth was also reduced, although not significantly (Fig. 6A). Erlotinib/RAPTA-C 
combination treatments at both dose-ratios resulted in a decrease in MVD, although this decrease was only sig-
nificant for combination II (34% inhibition; vs. CTRL; **P < 0.01; Fig. 6C). Quantification of IHC samples stained 
for the proliferation marker Ki67 showed a significant decrease in the percentage of Ki67+ tissue for combination I 
only (16% inhibition vs. CTRL; **P < 0.01; Fig. 6D).
Inhibition of tumor growth in a murine xenograft model by erlotinib/RAPTA-C combinations. 
The anti-tumor activity of erlotinib/RAPTA-C combinations (erlotinib at 5 mg/kg/day and RAPTA-C at 100 mg/
kg/day; referred to as combination II; erlotinib at 10 mg/kg/day and RAPTA-C at 100 mg/kg/day; referred to 
as combination III) was further investigated in nude mice xenografted with A2780 tumors. Treatment with 
combination II and III resulted in similar levels of additive tumor growth inhibition (48 and 53%, respectively; 
**P < 0.01 vs. CTRL; Fig. 7A), whereas treatment with erlotinib 5 mg/kg and 10 mg/kg, or RAPTA-C (100 mg/kg) 
as mono-therapies inhibited tumor growth by only 27%, 25%, and 37%, respectively. Notably, the average body 
weight of the mice measured on the last day of the experiment was not significantly affected by any of the treat-
ments, indicative of a lack of drug toxicity (Fig. 7B). Assessment of staining for CD31 in tumor sections revealed 
that the combination treatment significantly decreases MVD (by 30%), whereas the mono-therapies had little 
effect (*P < 0.05; Fig. 7C). Furthermore, assessment of the density of Ki67+ nuclei in tumor sections revealed a 
decrease in the density of proliferating cells (27% inhibition; *P < 0.05; Fig. 7D). These results indicate that the 
erlotinib/RAPTA-C combination reduces tumor growth via both antiangiogenic and anti-proliferative effects.
Figure 7. Inhibition of A2780 tumor growth in nude mice by erlotinib, RAPTA-C and their combination 
treatment. (A) Resected tumor volume of each treatment group as the percentage control on treatment day 12. 
N = 5–7 in all treatment groups. Control tumors were treated i.p. with 4% DMSO in NaCl (One-way ANOVA 
with Tukey’s multiple comparisons test: F(5,33) = 4.145, P = 0.0050). Pharmacokinetic studies in mice revealed 
a plasma half-life time of 1.5–3 hours after ingestion for erlotinib and 10.39–12.21 hours after ingestion for 
RAPTA-C16,69. (B) Body weight (g) measured at treatment day 12. (C) Microvessel density (MVD) analysis in 
combination III treated tumors represented as the number of vessels per mm2 of vascularized tumor area and 
represented as percentage of control. (D) Analysis of staining for the proliferation marker Ki67 in combination 
III treated tumors shown as the density of Ki67 positive nuclei per image field and represented as percentage 
CTRL. (E) Representative images of IHC staining for the endothelial cell marker CD31 (brown) counter-stained 
with haematoxylin (purple/blue). (F) Representative images of IHC staining for Ki67 (brown/orange) counter-
stained with haematoxylin (purple/blue). III indicates the combination erlotinib 10 mg/kg/day + RAPTA-C 
100 mg/kg/day in all graphs. Error bars represent SEM and *P < 0.05 indicates significance vs. CTRL. Statistical 
analysis was performed using a one-way ANOVA with post-hoc Tukey’s multiple comparison test (A), or an 
unpaired, one-tailed t-test with Welch’s correction.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7:43005 | DOI: 10.1038/srep43005
Discussion
An in vitro high-throughput screening-study revealed potential synergistic interactions between the EGFR inhib-
itor erlotinib and the broad acting organometallic compound RAPTA-C. In the present study, we performed an 
in-depth investigation of this drug combination and demonstrate their strong synergistic antitumor efficacy in 
preclinical tumor models, including one drug-resistant tumor model.
Previous studies have shown anti-angiogenic and anti-tumor effects after treatment with erlotinib and cispla-
tin. Combinations of these two drugs showed enhanced anti-angiogenic activity in non-small cell lung cancer 
(NSCLC) cells due to decreased VEGF levels and was evidenced by a decrease in the vessel density of NSCLC 
tumor xenograft samples50. We have previously demonstrated that RAPTA-C and other related Ru(II) compounds 
exhibit anti-angiogenic activity23. Furthermore, the Ru(III) complex NAMI-A has been shown to induce apop-
tosis in the spontaneously transformed human endothelial cell line, ECV30451. Synergistic interactions have pre-
viously been reported between KP1339 and the multi-kinase inhibitor sorafenib in hepatoma cancer both in 
vitro and in vivo26. Moreover, our previous screen did not show synergy in ECs when sorafenib, sunitinib and the 
mTOR inhibitor BEZ-235 were tested in combination with RAPTA-C at various dose ratios in our experimental 
setting34.
The analysis of the cellular uptake of ruthenium via inductively coupled plasma mass spectrometry (ICP-MS) 
revealed that the co-administration of erlotinib with RAPTA-C significantly enhances the uptake of Ru in both 
A2780 and A2780cisR cancer cell lines as compared to the Ru uptake of RAPTA-C administration alone (Fig. 2B). 
These results concur with previous studies which identified increased cellular uptake of Ru as one of the mecha-
nisms leading to synergistic interactions between KP1339 and sorafenib26.
Our mechanistic analysis suggests two pathways by which the combination of erlotinib and RAPTA-C 
impair the growth of different cell types. While significant apoptosis induction was seen in endothelial ECRF24 
and HUVEC cells, ovarian cancer A2780 and A2780cisR cells showed DNA bridges that prevent cytokinesis. 
Future investigation, possibly by live cell imaging, will have to uncover the precise origin of these DNA bridges. 
Nevertheless, since cytokinesis failure leads to a p53-dependent cell cycle arrest (via the hippo pathway) and cell 
senescence52,53, we postulate that growth impairment seen in A2780 and A2780cisR is due to senescence, consist-
ent with the lack of apoptotic cells.
The investigation of the anti-tumoral activity of varying dose ratios of combinations of erlotinib and 
RAPTA-C revealed effective inhibition of tumor growth in both A2780 and A2780cisR tumors grown in the 
CAM model. Differences in response between cell lines and dose ratios indicate that drug dose ratios can dra-
matically impact the overall efficacy of a drug combination and, more importantly, that higher drug doses do 
not necessarily correlate to higher efficacies, as observed in the in vitro assays. These results suggest that by using 
optimal drug dose ratios it is possible to target both the endothelial and tumor cells more efficiently. In this case, 
the inhibition of MVD limits tumor growth to a certain extent, however, part of the mechanism of drug action 
is also through the direct targeting of tumor cells. The microvessel density (MVD) in treated A2780 tumors, 
quantified by staining for the endothelial cell marker CD31, revealed that treatment with combinations of erlo-
tinib and RAPTA-C decreased MVD by 37% (combination I; **P < 0.01; Fig. 5D) and by 34% (combination II; 
*P < 0.05; Fig. 5D). We have previously described the activity of RAPTA-C as single drug therapy in the same 
model when administered at 200 μg/kg/day for 5 consecutive days. A decrease in MVD of approximately 80% 
was observed which corresponded to a tumor growth inhibition of 82%22, however, a longer treatment duration 
was required compared to when RAPTA-C is administered in combination with erlotinib. Moreover, succesful 
translation of anti-tumor efficacy to a nude mice A2780 xenograft model was achieved since treatment with erlo-
tinib/RAPTA-C resulted in significant tumor growth inhibition, reduced MVD, and a reduction in proliferating 
tumor cells (Fig. 7).
Taking into account the in vitro results of combination II in both endothelial and cancer cell types (Figs 1 
and 3, i.e. combination II treatment inhibits viability in both cell types, while enhancing apoptosis induction in 
endothelial cells, and increasing ruthenium uptake together with significantly increasing the percentage of cells 
with DNA bridges or micronuclei in tumor cells), the in vivo activity seen in all in vivo models results from varied 
mechanisms of actions in tumor cells and their microenvironment (Fig. 8).
In the in vivo models tested, MVD decreased significantly following treatment with the combination therapy 
whereas endothelial cell mobility was not affected (Supplementary Figure 1B), which is consistent with previous 
studies34. Supporting evidence suggests that inhibition of cell mobility alone does not have a therapeutic effect 
whereas the inhibition of endothelial cell viability alone does54. This evidence, together with the data presented 
here, indicates that inhibition of cell viability may be more dominant in accounting for an angiostatic anti-tumor 
effect as compared to inhibition of cell mobility.
In conclusion, erlotinib and RAPTA-C combination therapy synergistically inhibits endothelial and ovarian 
carcinoma cell proliferation, but does not affect cell mobility. Furthermore, the drug combination was shown 
to target angiogenesis in in vivo bioassays and in tumor growth inhibition models. RAPTA-C was previously 
shown to exhibit anti-metastatic activity, as well as having activity against primary tumors, to inhibit angiogen-
esis in various models and to have  a direct cytotoxic effect on tumor cells while showing little toxicity16,22,23,34. 
Consequently, RAPTA-C may serve as a good alternative to platinum-based drugs in combination therapies, 
especially in ovarian carcinoma, where increased activity of EGFR targeting drugs have been observed when 
combined with cytotoxic agents55,56.
Methods
Compounds. Erlotinib was purchased from LC laboratories (Woburn, MA, USA) and was dissolved in ster-
ile DMSO at a concentration of 15 mg/ml. Aliquots were stored in −80 °C and thawed prior to each experiment. 
RAPTA-C (Ru(η6-p-cymene)Cl2(pta)], (pta = 1,3,5-triaza-7-phosphaadamantane) was synthesized and purified 
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as described previously22. RAPTA-C powder was freshly dissolved in DMSO at 100 mg/ml before each experi-
ment. The maximum DMSO percentage was 0.14% and showed minimal activity in the performed assays.
Cell cultures. Immortalized human vascular endothelial cells (ECRF24) were cultured in medium containing 
50% DMEM and 50% RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin (Life Technologies, Carlsbad, California, USA). Human ovarian carcinoma cells were cultured in 
DMEM (A2780) and RPMI-1640 (A2780cisR) supplemented as above. HEK-293 cells were cultured in DMEM 
and supplemented as above. Human umbilical vein endothelial cells (HUVEC) were isolated from human umbil-
ical cords as previously described and cultured in 0.22 μm filtered RPMI-1640 medium supplemented with 10% 
human serum (HS), 10% FBS, 1% penicillin/streptomycin and 2 mM L-glutamine (Life Technologies)57. PBMCs 
were freshly isolated as previously described and cultured in IMDM supplemented with 10% FBS, 1% penicillin/
streptomycin and 0.05 β-mercaptoethanol58. ECRF24 and HUVEC were always cultured on 0.2% gelatin coated 
surfaces. All cell lines were maintained in a humidified incubator (5% CO2) at 37 °C.
Cell viability, cell migration, and apoptosis. For cell viability experiments, cells were seeded in the 
inner 60 wells of a 96-well culture plate at a density of 2.5–10 × 103 cells/well (depending on cell type) and grown 
for 24 h. Cells were allowed to grow for an additional 72 h in the presence of medium or drugs after which cell 
viability was assessed with the CellTiter-Glo luminescence assay (Promega, Madison, WI, USA). Cell response to 
drug treatment was determined based on normalizing the luminescence signal in the treated wells as compared 
to medium controls.
Cell migration was assessed with the wound healing assay as previously described59. ECRF24 cells were seeded 
at a density of 30 × 103 cells/well in a 96-well culture plate and grown overnight to confluence. A scratch wound 
was made on the confluent cell layer with a sterile scratch tool (Peira Scientific Instruments, Beerse, Belgium) 
and drugs or medium was applied to the cells. Scratch wound surfaces were automatically imaged with a Leica 
DMI3000 microscope (Leica, Rijswijk, Netherlands) at 5x magnification using Universal Grab 6.3 software 
(DCILabs, Keerbergen, Belgium). Images of scratch wounds were taken at T = 0 h and T = 6 h and scratch sur-
faces were analyzed by Scratch Assay 6.2 (DCILabs). Cell migration was quantified by calculating the absolute 
wound closure (initial minus final scratch surface) and values were presented as the percentage of medium treated 
control wound closure.
Flow cytometry analysis was performed to identify cell cycle stages including apoptotic fractions. Cells were 
seeded in 24-well plates at a density of 20–40 × 103 cells/well and incubated for 24 h. Medium or drugs were 
applied and cells were incubated for an additional 72 h. Cells were harvested by trypsinization, suspended in 70% 
ethanol and incubated for 2 h at −20 °C. Cell pellets were then re-suspended in DNA extraction buffer contain-
ing 90 parts 0.05 M Na2HPO4, 10 parts 0.025 M citric acid, 1 part 10% Triton-X100, (pH 7.4) and incubated for 
20 min at 37 °C. Propidium iodide (PI, 20 μg/ml) was added and cells were analyzed with a FACSCalibur flow 
cytometer (BD Biosciences) in the FL2 channel. Apoptotic cells were defined as having subG1 DNA staining and 
quantified with CellQuest Pro software (BD Biosciences). For cell growth monitoring, A2780 and A2780cisR 
cells were seeded at 10000 c/well in a 96-welll plate and allowed to attach overnight followed by treatment of the 
cells with the following conditions: DMSO control, 5 μM erlotinib, 10 μM erlotinib, 10 μM RAPTA-C, 100 μM 
RAPTA-C, combination I and combination II. Photographs of wells were taken using LEICA DMI 3000B before 
Figure 8. Schematic representation of cellular mechanism involved in the activity of erlotinib and 
RAPTA-C combinations. In ECRF24 cells, DNA damage may lead to failure to progress through G1/S 
checkpoint and therefore induction of apoptosis. In A2780 and A2780cisR cells mitotic defects lead to the 
formation of DNA bridges and micronuclei. Via the formation of DNA bridges, cytokinesis might be blocked 
leading to senescence.
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treatment, then at 24 h, 48 h and 72 h after treatment. To quantify cell density, Scratch Assay software (DCI labs) 
was used, which reports cell covered areas (μm2).
Stress fibre formation assay. A2780 and A2780cisR cells were seeded in a 24-well plate and allowed 
to adhere overnight. Cells were then pretreated for 24 h with the following conditions: DMSO control, 5 μM 
erlotinib, 10 μM erlotinib, 10 μM RAPTA-C, 100 μM RAPTA-C, combination I and combination II. Cells were 
washed with PBS, then fixed with 1% paraformaldehyde (Electron Microscopy Sciences-Aurion, Hatfield, PA) for 
20 min and consequently permeabilized with 0.1% Triton x-100 (Amresco, Solon, Ohio) for 10 min at 37 °C. Cells 
were incubated with Rhodamine-Phalloidin (Invitrogen, Oregon, USA) and DAPI (Invitrogen, Oregon, USA) 
in warmed 0.1% bovine serum albumin for 40 min. Cells were observed and photographed using a fluorescence 
microscope (LEICA DFC 345FX).
Immunoblotting. A2780 cells were seeded in 6-well plates and allowed to adhere overnight. Cells were pre-
treated either with DMSO control, 5 μM erlotinib, 100 μM RAPTA-C or combination of 5 μM erlotinib and 100uM 
RAPTA-C for 2 h at 37 °C. Cells were lysed in radioimmunoprecipitation assay buffer (25 mM Tris (pH 7–8), 
150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton-X-100) supplemented with HaltTM Protease/
Phosphatase inhibitor cocktail (Thermo Scientific, Rockford, USA) on ice and collected. Cell lysate was vortexed 
and snapfrozen in liquid nitrogen followed by sonication at 20 Amp for 10 s on 10 s off. Supernatant was col-
lected by centrifugation at 15,000 g at 4 °C for 10 minutes. Protein concentration was determined using the Micro 
BCA™ Protein Assay Kit (Thermofisher Scientific, Rockford, USA). Equal amounts of protein were resolved on 
SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was blocked with 5% bovine serum 
albumin in TBS-T and incubated with primary antibodies against total and phospho- FAK, AKT (Cell Signalling, 
Danvers, MA) and ERK (New England, Biolabs, Ipswich, MA) at 4 °C overnight with constant rolling. The house-
keeping protein GAPDH was used as internal control (Cell Signalling, Danvers, MA). The membrane was washed 
with TBS-T 3 × 20 min, incubated with IRdye® 680RD goat anti-rabbit secondary antibody (LICOR, Westburg, 
EU) for 30 min at room temperature with constant rolling and detected by the Odyssey® infrared imaging system.
Cellular uptake of Ruthenium-102. Cells were seeded in 6-well cell culture plates with either 5 × 105 
(ECRF24 and A2780cisR) or 3 × 105 (A2780) cells per well and allowed to adhere overnight. Subsequently, cells 
were treated with either medium (CTRL), single drug treatment of RAPTA-C or the combination of erlotinib/
RAPTA-C and incubated for 5 h. Cells were then washed 3 times with ice cold phosphate-buffered saline (PBS) 
and detached using PBS-Based Enzyme Free-Cell Dissociation Solution (Millipore™ Specialty Medium, Cat. # 
S-014-B). Next, cell lysis was achieved using the ‘freeze-thaw’ method, i.e. by performing 5 cycles of cooling the 
cells at −20 °C for 20 min and warming the cells at +37 °C for 20 min. The cell lysate was then stored at −20 °C 
until the day of the analysis.
Ten μl of each sample was isolated for protein quantification using the Quick Start™ Bradford Protein Assay 
based on the manufacturer’s instructions. The samples were subsequently digested for 3 h at 37 °C by adding 150 μl 
of 65% nitric acid. Following digestion, each sample was transferred to a 15 mL tube and diluted with water 
containing (1 ppb indium as an internal standard) to a final solution containing 3% nitric acid. ICP-MS was 
performed using an Elan DRC II ICP-MS instrument (Perkin Elmer, Switzerland) equipped with a Meinhard 
nebulizer and a cyclonic spray chamber.
Photodynamic therapy (PDT)-induced vessel sprouting on the chicken chorioallantoic 
membrane (CAM). The experiments were carried out in accordance with relevant guidelines and regu-
lations. The use of the CAM model in the Netherlands does not require the approval of the experimental pro-
tocol. Visualization of the CAM vasculature and irradiation with light during PDT was performed under an 
epi-fluorescence microscope (Eclipse E 600 FN; Nikon AG, Tokyo, Japan) with objectives (Plan Apo 4 ×/0.2, 
working distance: 20 mm or Plan Fluor 10 ×/0.3, working distance: 16 mm; Nikon AG), as previously described60. 
Shortly, PDT was performed using Visudyne® (Novartis Pharma Inc., Hettlingen, Switzerland) with a 5 J/cm2 
light energy dose at an irradiance of 35 mW/cm2 (λex = 420 ± 20 nm, λem ≥ 470 nm) on EDD11. The irradi-
ation area was limited to a circular spot of 0.02 cm2 using an optical diaphragm. Directly after PDT, 20 μl of 
drugs or drug combinations were administered intravenously. Visualization of blood vessels was performed 
24 h after treatment (EDD12) through fluorescence angiography after intravenous (i.v.) injection of fluorescein 
isothiocyanate dextran (FITC-dextran, 20 kD, 20 μl, 25 mg/ml, Sigma-Aldrich). A volume of 20 μl of India ink 
from Pelikan (Witzikon, Switzerland) was administered in the embryonic cavity to enhance vascular contrast. 
Fluorescence images were taken using a pco.1300 12-bit CCD camera (Gloor Instruments AG, Usler CH) run by 
Micro-Manager 1.4 (National Institutes of Health, Bethesda, MD, USA)61. Image processing and quantification 
of the fluorescence angiographies was achieved by using a macro written in ImageJ (version 1.40 a; National 
Institutes of Health, Bethesda, MD, USA), as previously described62. The parameters number of sprouts, average 
segment length and branching points per mm2 were quantified. Effects on the mature vasculature in the CAM 
were assessed through FITC-dextran visualization of the surrounding (non-PDT treated) vasculature 24 h after 
i.v. drug administration.
Human ovarian carcinoma grown on the chicken chorioallantoic membrane (CAM). Fertilized 
chicken eggs were incubated in a hatching incubator (relative humidity 65%, 37 °C), as previously described63. 
On embryo development day (EDD) 8, A2780 or A2780cisR cells were prepared in 25 μL hanging spheroids 
containing 106 cells in 20% Methocel (Sigma-Aldrich) and 80% serum free RPMI-1640 medium. The spheroids 
were then incubated for 3 h and transplanted on the surface of the CAM. Vascularized three-dimensional tum-
ors were visible 3 days after tumor cell implantation and randomized on EDD 11, when treatment was initiated. 
Tumors were treated on EDD 11 and 12 (referred to as treatment day 1 and 2) by 20 μl intravenous injection into 
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a main blood vessel of the CAM. Erlotinib and RAPTA-C were freshly prepared and pre-mixed in 0.9% NaCl. 
The injected doses (10–20 μg/kg for erlotinib and 21.6–216 μg/kg for RAPTA-C) were adjusted to the normalized 
embryo weight at EDD 11/12 (4.27 g). Control tumors were treated with vehicle (0.14% DMSO in 0.9% NaCl). 
Tumors were monitored daily for 8 days and tumor size was calculated with the formula: volume = [large diam-
eter] x [perpendicular diameter] 2 × 0.52. At EDD 18: (i) the embryos were sacrificed and weighed and (ii) the 
tumors were resected, weighed and fixed in zinc-fixative for additional analysis.
Human ovarian carcinoma xenograft model. All methods were carried out in accordance with relevant 
guidelines and regulations and experimental protocol was approved by the Committee for Animal Experiments 
for the Canton Vaud, Switzerland. Female Swiss nu/nu mice ages 6–8 weeks were obtained from Charles River 
(weight 20–30 grams). Mice were inoculated in the right flank with 100 μl RPMI containing 5 million A2780 cells. 
Tumors treatment was initiated 6 days after inoculation, when palpable tumors had appeared. Mice were treated 
daily by oral gavage with erlotinib 10 mg/kg (suspended in sterile water with 0.5% (w/v) methyl cellulose and 
0.1% (v/v) tween 80), by i.p. injection with RAPTA-C 100 mg/kg (freshly dissolved in DMSO and diluted in 0.9% 
NaCl) both in a total volume of 100 μl or the combination of both treatments. The dose of RAPTA-C was selected 
based on previous experiments of RAPTA-C in a murine xenograft model (LS174T) where erlotinib 5 mg/kg/
day and RAPTA-C 40 mg/kg/day showed synergy but was minimally effective34. Therefore, in this study, the dose 
of RAPTA-C was increased to 100 mg/kg/day. Moreover, the erlotinib dose of 10 mg/kg/day was selected as a 
reduced dose to show 10–40% anti-tumour efficacy, as seen in in vitro assays, and being well below the reported 
MTD of 100 mg/kg/day in mice64. Mice in the control group were treated by i.p. injection of 0.9% NaCl contain-
ing 4% DMSO, to mimic the solution of RAPTA-C. Mice were monitored daily for tumor size and body weight.
Immunohistochemistry. Immunohistochemical (IHC) staining of CAM tumors with endothelial cell 
marker CD31, to detect blood vessels, and with proliferation marker (in cell nuclei) Ki67 was performed as pre-
viously described65. Briefly, tumors were fixed overnight in zinc fixative solution, embedded in paraffin and 5 μm 
sections were stained. Sections were blocked with 5% bovine serum albumin (BSA) in PBS followed by incubation 
with primary antibodies against CD31 (1:200; clone SZ31, Dianova, Hamburg, Germany). Secondary donkey 
anti-rat biotinylated antibodies (1:200; Jackson, Suffolk, UK) were then incubated, followed by streptavidin-HRP 
(1:50; Dako, Glostrup, Denmark) and visualized by 3,3′-diaminobenzidine (DAB), resulting in a brown-colored 
precipitate at the antigen site. Sections were stained separately for proliferation marker with primary antibod-
ies against Ki67 (rabbit anti-human Ki67, 1:100, clone SP6; Thermo Scientific) and subsequent incubation with 
secondary swine anti-rabbit biotinylated antibodies (1:200; Dako, Glostrup, Denmark). Ki67+ nuclei were vis-
ualized by DAB following streptavidin-HRP staining. Microvessel density (MVD) in CAM and mouse tumors 
was assessed by ImageJ quantification of representative images (20x objective) within vascular hotspots using 
the colour deconvolution plugin, as previously described66. When necessary, vessel counts were corrected for the 
presence of necrotic patches or holes in an image. In mouse tumors, the density of Ki67 positive nuclei per image 
field (20x objective) was also assessed by the colour deconvolution in ImageJ. In CAM tumors, the percentage of 
Ki67 positive tumor areas was calculated by measuring images (4x objective) of the total tumor area and areas 
with Ki67 staining in ImageJ.
Statistical analysis. The data is presented as the mean of multiple independent experiments (±SEM). 
Significance was determined using the one-way or two-way ANOVA test with post-hoc Tukey’s multiple compar-
ison test, or post-hoc Dunnett’s multiple comparison test between the combination and control and an unpaired t 
test with Welch’s correction (Graphpad Prism). *P values lower than 0.05 and **P lower than 0.01 were considered 
statistically significant and are indicated versus the control in all figures. Combination index (CI) values were 
determined by the Chou-Talalay method using the Compusyn software, as previously described67,68. When the 
single drug efficacy of a compound was above 100% (i.e. stimulatory), a value of 0.001 was used for the fraction 
affected in order to calculate the CI values. In the case of A2780cisR, which was not responsive to RAPTA-C, 
artificial values of efficacy were used with a maximal effect of 2% for the highest dose of 200 μM.
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